



P R E S S R E L E A S E

Four projects, accredited by Lyonbiopole, obtain public funding from the 19th Call for Projects of the Single Inter-Ministry Fund (FUI)

Lyon/Grenoble, on March 27, 2015 – After their accreditation by Lyonbiopole, worldwide competitiveness cluster, the new projects COLOMATRIX, COINSIDE, DOGTOMAN and ROBOT-PCR have been selected by the FUI. Since 2005, Lyonbiopole has accredited 169 multi-partner R&D projects for a total R&D investment of € 777 million of which € 312 million have been obtained.

4 new R&D projects, accredited by Lyonbiopole and submitted to the 19th FUI Call for Projects, benefit from public funding from the French State, local authorities among which the Rhône-Alpes Region, Métropole de Lyon, Métropole de Grenoble, General Council of Isère and FEDER European funds.

COLOMATRIX (AAP19 FUI)

Innovative medical device for digestive surgery

Partners: Biom'Up (project leader), MDB Texinov, Voxcan, Laboratoire Biotis/CICIT, Université Claude Bernard Lyon1 – Laboratoire IMP

COLOMATRIX project is accredited by Lyonbiopole and co-accredited by Techtera. It aims at preventing one of the major causes of morbidity and mortality in digestive surgery. An innovative medical device will combine high tech polymers and textiles for unique biological and mechanical properties.

COINSIDE (AAP19 FUI)

Innovative drug discovery for cognitive impairments

Partners: SynapCell (project leader), Cellipse, Grenoble Institut des Neurosciences (INSERM U836 – UJF – CEA – CHU)

Accredited by Lyonbiopole, COinside aims to develop an innovative solution with high predictive value for assessing the efficacy of drug candidates on cognitive processes in neurological and psychiatric diseases. This new solution will be developed by combining electroencephalographic biomarkers detected on predictive models of the targeted diseases.

LYONBIOPOLE

PRESS RELEASE

DOGTOMAN (AAP19 FUI)

Development of innovative treatment for sarcomas: therapeutic approaches translated from dogs to humans

Partners: ECRINS Therapeutics (project leader), Oncovet Clinical Research, Centre Léon Bérard et l'Institut de Génétique et Développement de Rennes

Accredited by Lyonbiopole and co-accredited by NSL competitiveness cluster, the project Dog To Man aims to develop an innovative treatment for sarcomas via a translational research in dogs and humans. The results of the clinical trial carried out in dogs will be translated to human patients in order to boost the chances of successfully developing innovative drug ET-D5 for the treatment of sarcomas. Moreover, it's anticipated that these results will allow to quickly bring on the market a veterinary drug for the treatment of sarcomas in companion animals (dogs). The success of the project will hinge on the complementarity of the consortium members – experts in human and veterinary oncology, biology, genetics and pharmacology of cancer, as well as in the field of drug and biomarker development.

ROBOT-PCR (AAP19 FUI)

Automated real-time analysis of the food sanitary quality

Partners: ADNUCLEIS (project leader), Copalis, ENILV and ENILBIO

Accredited by Lyonbiopole and NSL, Robot-PCR project aimed to develop real time PCR as a standard in Food industry regarding pathogens and routine contaminant analyzes through DNA extraction and gene amplification. This standard answers to a strong need from industrials which want to access easily to robust technologies for process controls and food sanitary quality. The objective is to conceive new procedures for fast analyzes, automated and robotized, allowing a real time monitoring by molecular biology professionals and taking place to traditional cultural methods which are too long.

An update on projects accredited by Lyonbiopole and funded

Since 2005, Lyonbiopole has accredited **169** R&D projects, representing a total investment around of € **777** million and have obtained € **312** million of public funding.

→ FUI calls for projects

49 projects of a total € **221** million investment received public funding totaling € **89** million.

→ ANR calls for projects

106 projects, corresponding to € **183** million of investments and that have obtained € **60** million public funding from the National Research Agency (ANR).

LYONBIOPOLE

P R E S S R E L E A S E

→ ISI Bpifrance and PSPC

6 projects accredited by Lyonbiopole, representing an investment totaling € 351 million, obtained a total € 150 million public funding.

→ Other projects

7 projects accredited by Lyonbiopole and of a total € 22 million investments, obtained a total of € 13 million in funding from the European Commission, Bpifrance and local authorities (except FUI projects).

About Lyonbiopole

As a biocluster, Lyonbiopole is the one-stop shop for healthcare innovation in Rhône-Alpes, France. It aims to support the emergence and development of innovative technologies, products and services in 4 main strategic areas: human medicine, veterinary medicine, *in vitro* diagnostics, medical devices and medical technologies. Focused on infectious diseases since its creation in 2005, Lyonbiopole is now supporting ambitious projects and companies in other fields like cancer, nutrition, metabolic diseases and neurosciences. In 2014, Lyonbiopole represented a community of 176 members: 4 world-class leaders as Lyonbiopole's founders (Sanofi Pasteur, bioMérieux, Merial, BD) – 18 Research Centers including 3 Hospital University Centers and almost 154 SMEs. Lyonbiopole received in November 2014, the Gold label awarded by the "European Cluster Excellence Initiative".

More information: www.lyonbiopole.com

Press Contacts

Florence Portejoie - +33 (0)1 58 18 32 58 / 06 88 84 81 74 - fportejoie@hbcomcorp.fr
Stéphanie Pelège - +33 (0)4 72 76 53 41 - info@lyonbiopole.com